A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
Status:
Withdrawn
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, open-label, phase II study of in adult patients who have successfully
undergone R0/R1 resection of PDAs following neoadjuvant chemotherapy and completion of
adjuvant chemotherapy. Within 1-3 months of treatment completion, patients will be enrolled
and randomized at a 1:1 ratio to receive durvalumab versus observation.